Skip to main content

Table 1 The comparison of 24 months survival and galectin-3 expression in selected groups of patients.

From: Galectin-3 and cyclin D1 expression in non-small cell lung cancer

Survival Positive
galectin-3
expression n (%)
Negative galectin-3 expression n (%) Chi2
Yatesa
p Cox Mantel
All examinated patients with NSCLC
< 24 months 8 (44.44%) 12 (41.38%) 0.01 0.922 0.841
≥ 24 months 10 (55.56%) 17 (58.62%)    
The patients with squamous cell carcinoma
< 24 months 5 (45.45%) 5 (38.46%) 0.00 0.944 0.612
≥ 24 months 6 (54.55%) 8 (61.54%)    
The patients with adenocarcinoma
< 24 months 2 (50%) 6 (54.55%) 0.18 0.667 0.695
≥ 24 months 2 (50%) 5 (45.45%)    
Stage I
< 24 months 1 (33.33%) 2 (14.29%) 0.00 0.960 0.434
≥ 24 months 2 (66.66%) 12 (85.71%)    
Stage II      
< 24 months 2 (40%) 3 (100%) 0.89 0.345 0252
≥ 24 months 3 (60%) 0 (0%)    
Stage III      
< 24 months 2 (28.57%) 5 (55.56%) 0.33 0.567 0.275
≥ 24 months 5 (71.43%) 4 (44.44%)    
Stage IV      
< 24 months 3 (100%) 2 (66.67%) 0.00 1.00 0.341
≥ 24 months 0 (0%) 1 (33.33%)